REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:

  • UBS Global Biopharma Conference in London– fireside chat Tuesday, November 17 at 14:00 GMT (9:00 am ET).
  • 2026 Jefferies Global Healthcare Conference in London – presentation on Wednesday, November 18 at 14:30 GMT (9:30 am ET)
  • DNB Carnegie Healthcare Conference in Oslo – fireside chat on Tuesday, November 24 at 13:20 CET (7:20 am ET).
  • SEB Healthcare Seminar in Stockholm– fireside chat on Wednesday, November 25 at 10:40 CET (4:40 am ET).

Live audio webcasts will be available to investors and the general public on Alvotech’s website on our Events and Presentations page: https://www.alvotech.com/events in the 2026 Q4 section. After the live webcasts, a recording will also be available for up to 90 days.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website.

REYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:

  • UBS Global Biopharma Conference in London– fireside chat Tuesday, November 17 at 14:00 GMT (9:00 am ET).
  • 2026 Jefferies Global Healthcare Conference in London – presentation on Wednesday, November 18 at 14:30 GMT (9:30 am ET)
  • DNB Carnegie Healthcare Conference in Oslo – fireside chat on Tuesday, November 24 at 13:20 CET (7:20 am ET).
  • SEB Healthcare Seminar in Stockholm– fireside chat on Wednesday, November 25 at 10:40 CET (4:40 am ET).

Live audio webcasts will be available to investors and the general public on Alvotech’s website on our Events and Presentations page: https://www.alvotech.com/events in the 2026 Q4 section. After the live webcasts, a recording will also be available for up to 90 days.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website.

Heineken N.V. reports the progress of transactions under its current
share buyback programme

Amsterdam, 2 November 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 26 October 2026 up to and including 30 October 2026 a total of 159,700 shares were repurchased on exchange at an average price of € 77.94. During the same period, 160,530 shares were repurchased from Heineken Holding N.V.

Up to and including 30 October 2026, a total of 9,510,681 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 679,219,878 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

 Enquiries  
Media Investors
Christiaan Prins Tristan van Strien
Director of Global Communication Global Director of Investor Relations
Marlous den Bieman Lennart Scholtus / Isabelle van Rongen
Head of Global Media, Issues and Crises Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com E-mail: investors@heineken.com
Tel: +31-20-5239355 Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

Independent Audit Validates Data Security Controls Across Xtract One View, SmartGateway, and Xtract One Gateway

TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced the successful completion of its System and Organization Controls (SOC) 2 Type II audit, conducted by an independent third-party auditing firm. The audit evaluated Xtract One’s internal security controls, data protection practices, and product architecture across its Xtract One View cloud platform, SmartGateway, and Xtract One Gateways.

For Fortune 500 companies, enterprise facilities, and the regulated environments Xtract One serves across healthcare, government, and large-scale deployments, the certification provides verified assurance that the telemetry, analytics, and operational data generated by Xtract One’s physical screening systems are protected by continuously tested, enterprise-grade security controls. Vendor data security documentation is a requirement of the procurement and onboarding process for organizations of this scale, and SOC 2 Type II certification addresses that requirement directly.

Developed by the American Institute of Certified Public Accountants (AICPA), a SOC 2 Type II audit examines a service organization’s internal controls over a continuous period rather than at a single point in time. The audit tests the operating effectiveness of those controls across security, availability, and confidentiality, providing documented evidence that a company consistently adheres to rigorous data protection standards throughout its operations.

“As Fortune 500 companies and large enterprise organizations continue to select Xtract One, we’re pleased to meet the advanced security requirements they bring to every vendor relationship,” said Peter Evans, CEO of Xtract One. “Organizations that keep security as a priority apply rigorous evaluation across every dimension of a solution, from operational considerations to IT integration to cybersecurity, and most importantly the overall effectiveness of the physical security program itself. SOC 2 Type II is an ongoing validation to those organizations that Xtract One delivers solutions that are as secure as they are effective.”

“Our customers trust us to protect the physical safety of their patrons, students, and patients,” said Joshua Douglas, SVP of Product and Engineering, Xtract One. “In today’s environment, physical security and data security are directly connected. The data flowing through our systems, the screening metrics, the system health analytics, the cloud communications, carries the same responsibility as the detection itself. SOC 2 Type II certification is our public commitment that we hold those controls to the same standard our customers expect from their enterprise technology partners.”

The audit covered Xtract One View, the Company’s centralized cloud management platform for fleet oversight, real-time analytics, and remote system management, as well as the connected hardware systems that feed it. The certification confirms that Xtract One’s cloud infrastructure and endpoint architecture operate under verified data privacy controls, proactive vulnerability management, and documented incident response protocols.

To learn more, visit www.xtractone.com.

About Xtract One
Xtract One Technologies is a leading technology-driven provider of threat detection and security solutions leveraging AI to deliver seamless and secure experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved “Walk-right-In” experiences while enhancing safety. Xtract One’s innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit www.xtractone.com or connect on Facebook, X, and LinkedIn.

About Threat Detection Systems
Xtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today’s world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security.

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance and customer contracts, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, but are not limited to, the risks detailed from time to time in the continuous disclosure filings made by the Company with securities regulations. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information, please contact:
Xtract One Inquiries: info@xtractone.com, http://www.xtractone.com
Investor Relations: Mark Kuindersma, LodeRock Advisors, mark.kuindersma@loderockadvisors.com, 519-501-0545
Media Contact: Kristen Aikey, JMG Public Relations, kristen@jmgpr.com, 212-206-1645

VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading licensed producer of premium cannabis products, is pleased to announce that it will be reporting its financial results for the period ended September 30, 2026 (“Q3 2026”) before market opening on Monday, November 16.  

Q3 2026 Conference Call

The Company will be hosting a conference call to discuss the results on Monday, November 16, 2026. Conference call details are as follows:

Time: 8:00 AM PCT / 10:00 AM EST
Conference ID: 45311
Local dial-in:  (+1) 289 514 5100
Toll Free N. America: (+1) 800 717 1738
Webcast: https://onlinexperiences.com/Launch/QReg/ShowUUID=CEB4A826-A47C-465A-BCF9-EE215FEF43CB

PSU Grant

On July 20, 2026, the Company announced that 686,786 performance share units held by certain executives had been forfeited and cancelled. On September 24, 2026, the Company granted 686,786 performance share units to such executives on substantially the same economic terms and vesting schedule as the forfeited performance share units.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is a Canadian leader in certified organic and premium cannabis, with a portfolio of trusted brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates the 125,000-square-foot Pacifica hybrid greenhouse in Delta, British Columbia, and the 47,500-square-foot Cascadia indoor facility in Hope, British Columbia, with current annual production capacity of approximately 15,500 kilograms of premium cannabis, expanding to 20,000 kilograms by mid 2027. Rubicon’s proprietary genetics, award-winning products and international certifications support its growth in Canada and regulated international markets.

For more information visit www.rubiconorganics.com.

CONTACT INFORMATION

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. Forward-looking information can be identified by the use of words such as “will”, “expected”, “anticipated”, “continue”, “positioned”, “opportunities”, “potential” or variations of such words or statements that certain actions, events or results may, could, would, should, might or will occur or be achieved. Forward-looking information includes, but is not limited to, statements regarding the timing of the release of the Company’s Q3 2026 financial results and the timing of the Company’s related conference call.

Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the risk that the timing of the release of the Company’s Q3 2026 financial results or the related conference call may change; changes in general economic or market conditions; shifts in consumer demand; changes in applicable laws or regulatory requirements governing the cannabis industry; the ability to obtain necessary approvals, including approval from the TSX Venture Exchange; and other risk factors described in the Company’s public disclosure filings available on SEDAR+ at www.sedarplus.ca. 

Readers are cautioned not to place undue reliance on such forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.

All forward-looking information in this press release is made as of the date hereof and is based on the beliefs, estimates, and opinions of management as of the date such statements are made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable law.

EDMONTON, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended September 30, 2026.

Highlights

  • Long-term Energy Supply Agreement (ESA) for 250 megawatts of capacity and energy with Meta Platforms, Inc. in support of a data centre
  • Subsequent to the quarter, the 100MW expansion at East Windsor received approval to operate in the Ontario market
  • Generated net cash flows from operating activities of $381 million and adjusted funds from operations (AFFO)1 of $306 million
  • Generated net income of $67 million and adjusted EBITDA1 of $553 million
  • Increased annual common share dividend by 2%, representing the 13th consecutive year of increase

CEO Message

Our third-quarter results reflect the continued execution of our strategy and the value of our diversified portfolio, with strong contributions from our Alberta, PJM and Ontario assets. Our portfolio pairs stable contracted cash flows with exposure to markets where growing electricity demand and tightening supply are creating meaningful upside.

Approximately 75% of our expected 2026 adjusted EBITDA is underpinned by long-term contracts. Indicative of our strategy of working with high-quality counterparties, 100% of our power purchase agreements are held with investment grade counterparties and over 70% are utilities or system operators. Our Energy Supply Agreement with Meta is the latest example of these efforts to secure longer-term cash flows across our core markets. Over the past 18 months, we have delivered on ~2 GW of contracted capacity with a weighted average contract life of approximately 15 years.

With a strong balance sheet and disciplined capital allocation, we are also evaluating opportunities to extract additional value from our existing sites through uprates, expansions and co-located battery storage. These opportunities support our focus on growth and shareholder returns. The 2% annual dividend increase announced in the second quarter marks the 13th consecutive year of increase.

Revised 2026 Annual Guidance

Priority 2026 targets Status at September 30, 2026
Generate financial
stabilityand strength

AFFO 3 of $890 million to $1,010 million $788 million ‎1
Adjusted EBITDA 3 of $1,565 million to
$1,765 million
$1,308 million ‎1
Execution of major  Sustaining capital expenditures 4
$270 million ‎1,‎2
turnarounds Revised target:
$350 million to
$370 million
Original target:
$290 million to
$330 million
 
Portfolio optimization Re-contract/contract natural gas generation
Maximize facility asset life and value
In July, the Company entered into a long-term ESA with Meta for 250 MW of capacity and energy in support of a data centre in Alberta.

In Q1 2026, the Company extended its summer tolling agreement for Arlington Valley from 2031 to October 2038. As part of this agreement, the facility will undergo a 35 MW capacity uprate.

Discussions with counterparties to supply energy solutions from across our fleet are in progress.

Expand flexible generation portfolio Continue construction on Ontario growth and commercial initiative projects
Continue to explore opportunities to build or acquire natural gas generation facilities
Construction is underway and the projects are progressing to meet their targeted completion dates. Subsequent to the quarter, the 100MW expansion at East Windsor received approval to operate in the Ontario market.
Grow renewables portfolio Continue construction of North Carolina growth projects
Continue to explore opportunities to build or acquire renewables facilities
Construction for the North Carolina solar projects continued into 2026. Commissioning activities for Hornet and Bear Branch Solar are progressing towards a Q4 2026 completion.
Advance balanced energy solutions such as low-carbon solutions Evaluate SMRs in Alberta

Continue to explore opportunities to co-locate with data centres across North America

Pre-feasibility study work for the Alberta SMR project with Ontario Power Generation remains on track, and we continue to evaluate the development opportunity through this project.

We remain in various stages of discussion with several prospective customers about the potential to co-locate or otherwise serve data centre demand at our sites across North America.

  1. For the nine months ended September 30, 2026.
  2. Net of partner contributions of $10 million and including our share of equity-accounted investments sustaining capital expenditures of $38 million.
  3. AFFO and adjusted EBITDA are non-GAAP financial measures. See Non-GAAP Financial Measures and Ratios.
  4. The Company revised its guidance range for 2026 sustaining capital expenditures reflecting unplanned outage work, primarily for the U.S. flexible generation fleet, and the advancement of a planned outage from 2027 into the fourth quarter of 2026 to ensure high reliability through 2027. The increase is event-driven, and a significant portion relates to insurable events. Insurance recoveries anticipated in 2026 and 2027, together with concessions from original equipment manufacturers (OEMs), are expected to meaningfully offset the cash impact.

Operational and Financial Highlights1

($ millions, except per share amounts) Three months ended
September 30,
Nine months ended
September 30,
  2026 2025 2026 2025
Electricity generation (Gigawatt hours) 2 14,485 13,374 36,090 31,951
Generation facility availability (%) 3 93 93 91 92
Revenues and other income 831 1,213 2,776 2,642
Net income 67 153 39 172
Net income attributable to shareholders of the Company 67 154 38 173
Basic earnings per share ($) 0.37 0.94 0.09 1.02
Diluted earnings per share ($) ‎4 0.37 0.94 0.09 1.01
Adjusted EBITDA ‎5 553 477 1,308 1,166
AFFO ‎5 306 369 788 822
AFFO per share ($) ‎5 1.94 2.37 5.03 5.53
Net cash flows from operating activities 381 404 907 757
Purchase of property, plant and equipment and other assets, net 167 147 642 576
Dividends per common share, declared ($) 0.7048 0.6910 2.0868 1.9948
  1. The operational and financial highlights in this press release should be read in conjunction with the Management’s Discussion and Analysis (MD&A) and the unaudited condensed interim financial statements for the nine months ended September 30, 2026.
  2. Gigawatt hours (GWh) of electricity generation reflects the Company’s share of facility output and includes GWh discharged from BESS.
  3. Facility availability represents the percentage of time in the period that the facility was available to generate power regardless of whether it was running and therefore is reduced by planned and unplanned outages.
  4. Diluted earnings per share was calculated after giving effect to outstanding share purchase options.
  5. The consolidated financial highlights, except for adjusted EBITDA, AFFO and AFFO per share were prepared in accordance with GAAP. See Non-GAAP Financial Measures and Ratios.

Revenues and other income decreased quarter-over-quarter due to unfavourable changes in unrealized fair value on commodity derivatives and emission credits, primarily in the U.S. flexible generation segment. Excluding these non-cash fair value changes, revenues and other income increased, driven by higher contributions from the U.S. flexible generation segment, where stronger PJM pricing and summer demand at Hummel Station and Rolling Hills and higher contracted revenues at Arlington Valley more than offset less favourable hedge settlements at La Paloma.

Adjusted EBITDA increased quarter-over-quarter primarily due to:

  • higher contributions from the Hummel Station and Rolling Hills facilities acquired in June 2025, reflecting stronger PJM power prices and summer demand in the third quarter and a full nine months of operations in 2026,
  • higher results in the Canada flexible generation segment, as favourable portfolio optimization, higher generation and pricing at Goreway, and contributions from the Ontario BESS projects that commenced operations in September 2025 more than offset the impact of lower Alberta spot power prices and lower generation,
  • partially offset by a lower contribution from La Paloma, where the financial hedges entered into following its acquisition settled less favourably than in 2025.

AFFO was $306 million and $788 million for the three and nine months ended September 30, 2026, respectively, compared with $369 million and $822 million in the corresponding periods in 2025. Despite higher adjusted EBITDA, as described above, AFFO for both the quarter and year-to-date periods was impacted by the following:

  • higher sustaining capital expenditures, primarily reflecting the heavy maintenance schedule for the Alberta fleet, rotor replacements at Rolling Hills and Harquahala, and a full year of planned maintenance at Hummel Station and Rolling Hills,
  • higher net finance expense,
  • current income tax expense of $35 million and $65 million for the three and nine months ended September 30, 2026, respectively, compared with income tax recoveries of $16 million and $72 million in the corresponding periods of 2025, reflecting higher taxable income due to lower tax depreciation, and
  • the non-cash straight-line recognition of capacity payments under the Arlington Valley summer tolling agreement, which contributed favourably to adjusted EBITDA, and which did not affect AFFO,
  • the year-to-date impacts were partially offset by the recognition of $174 million in Clean Technology ITCs for eligible Canadian renewables projects in the second quarter of 2026.

Analyst conference call and webcast

Capital Power will be hosting a conference call and live webcast with analysts on November 2, 2026 at 9:00 a.m. ABT (8:00 a.m. MT / 10:00 a.m. ET) to discuss the third quarter financial results. The webcast can be accessed at: https://edge.media-server.com/mmc/p/z44y8ypg/. Conference call details will be sent directly to analysts.

An archive of the webcast will be available on the Company’s website at www.capitalpower.com following the conclusion of the analyst conference call.

Non-GAAP Financial Measures and Ratios 

Capital Power uses (i) earnings before income tax expense, depreciation and amortization, net finance expense, foreign exchange gains or losses, gains or losses on disposals and other transactions, unrealized changes in fair value of commodity derivatives and emission credits, other expenses from our equity-accounted investments, acquisition and integration costs, and other items that are not reflective of the Company’s facility operating performance (adjusted EBITDA), and (ii) adjusted funds from operations (AFFO) as specified financial measures. Adjusted EBITDA and AFFO are both non-GAAP financial measures.

Capital Power also uses AFFO per share as a specified performance measure. This measure is a non-GAAP ratio determined by applying AFFO to the weighted average number of common shares used in the calculation of basic and diluted earnings per share.

These terms are not defined financial measures according to GAAP and do not have standardized meanings prescribed by GAAP and, therefore, are unlikely to be comparable to similar measures used by other enterprises. These measures should not be considered alternatives to net income, net income attributable to shareholders of Capital Power, net cash flows from operating activities or other measures of financial performance calculated in accordance with GAAP. Rather, these measures are provided to complement GAAP measures in the analysis of our results of operations from management’s perspective.

Adjusted EBITDA

Capital Power uses adjusted EBITDA to measure the operating performance of facilities and categories of facilities from period to period. Management believes that a measure of facility operating performance is more meaningful if results not related to facility operations are excluded from the adjusted EBITDA measure such as impairments, foreign exchange gains or losses, gains or losses on disposals and other transactions, unrealized changes in fair value of commodity derivatives and emission credits, acquisition and integration costs, and other items that are not reflective of the long-term performance of the Company’s underlying operations.

A reconciliation of adjusted EBITDA to net income is as follows:

($ millions) Three months ended
September 30,
Nine months ended
September 30,
  2026   2025   2026 2025  
Net income 67   153   39 172  
Depreciation and amortization 207   157   555 421  
Unrealized changes in fair value of commodity derivatives and emission credits 89   (13 ) 238 176  
Foreign exchange (gain) loss (2 ) 7   20 (16 )
Net finance expense 95   92   282 217  
Acquisition and integration costs –   4   – 41  
Loss on disposals and other transactions 17   5   17 12  
Other items1 45   37   142 110  
Other non-recurring items‎2 (2 ) –   – 4  
Income tax expense 37   35   15 29  
Adjusted EBITDA 553   477   1,308 1,166  
  1. Includes finance expense, depreciation expense and unrealized changes in fair value of derivative instruments from equity-accounted investments.
  2. For the three and nine months ended September 30, 2026, other non-recurring items reflect a partial reimbursement for a provision assumed in the acquisition of Hummel Station, LLC, related to overpayments to FERC and legal fees related to a dispute with a contractor regarding construction work on the Genesee Repowering project. The nine months ended September 30, 2025 reflects costs related to the end-of-life of Genesee coal operations.

AFFO and AFFO per share

AFFO and AFFO per share are measures of our ability to generate cash from our operating activities to fund growth capital expenditures, repayment of debt, and payment of common share dividends.

The Company’s AFFO definition includes government grants related to off-coal compensation to be received annually to 2030. During the second quarter of 2026, the Company updated the composition of AFFO and AFFO per share to reflect the introduction of similar government grants where cash grants form part of the operating returns on qualifying capital investment and support the Company’s cash generation and liquidity profile. As a result, AFFO and AFFO per share now include Clean Technology ITCs associated with eligible Canadian renewables projects.

The Company has included $174 million in government grants related to Clean Technology ITCs, representing approximately 30% of eligible Canadian renewables project costs. These amounts are included in AFFO and AFFO per share in the period in which the required filing with the applicable tax authority is completed, rather than when cash is received to eliminate timing variability associated with administrative processing. While Capital Power expects amounts ultimately received to be consistent with amounts filed, actual receipts may differ. The amendment did not impact previously reported AFFO or AFFO per share amounts.

AFFO represents net cash flows from operating activities adjusted to:

  • exclude timing impacts of cash receipts and payments that may impact period-to-period comparability by including deductions for net finance expense and current income tax expense, and excluding deductions for interest paid, deductions for income taxes paid and changes in operating working capital,
  • include our share of AFFO of equity-accounted investments and exclude distributions received from our equity-accounted investments which are calculated after the effect of non-operating activity equity-accounted investments debt payments,
  • include government grants which represent a portion of operating returns on capital investment recognized in the period that they are either contractually obligated to be received by Capital Power or the period in which Capital Power has completed the necessary filing with the applicable tax authority to eliminate timing uncertainty due to administrative filing processes,
  • exclude the tax equity financing project investors’ shares of AFFO associated with assets under tax equity financing structures so only Capital Power’s share is reflected in the overall metric,
  • deduct sustaining capital expenditures and preferred share dividends,
  • exclude the impact of fair value changes in certain unsettled derivative financial instruments that are charged or credited to our bank margin account held with a specific exchange counterparty,
  • exclude acquisition and integration costs, and
  • exclude other typically non-recurring items affecting cash flows from operating activities that are not reflective of the long-term performance of the Company’s underlying business.

A reconciliation of net cash flows from operating activities to AFFO is as follows:

($ millions except per share amounts) Three months ended
September 30,
Nine months ended
September 30,
  2026   2025   2026   2025  
Net cash flows from operating activities 381   404   907   757  
Add (deduct):        
Interest paid 95   87   254   202  
Change in fair value of derivatives reflected as cash settlement 4   —   10   7  
Realized gain on settlement of interest rate derivatives (12 ) —   (12 ) (17 )
Distributions received from equity-accounted investments (7 ) (9 ) (72 ) (47 )
Miscellaneous financing charges1 4   4   11   (2 )
Income taxes recovered (12 ) (11 ) (12 ) (14 )
Change in non-cash operating working capital (26 ) (77 ) (39 ) (23 )
  46   (6 ) 140   106  
Net finance expense 2 (87 ) (81 ) (258 ) (192 )
Current income tax (expense) recovery 3 (35 ) 16   (65 ) 72  
Sustaining capital expenditures 4 (87 ) (44 ) (232 ) (85 )
Preferred share dividends paid (7 ) (7 ) (22 ) (20 )
Government grants 5 50   50   224   60  
Remove tax equity interests’ respective shares of AFFO 1   (1 ) —   (4 )
AFFO from equity-accounted investments 43   38   98   101  
Acquisition and integration costs 6 —   3   (1 ) 41  
Other non-recurring items ‎7 1   (3 ) (3 ) (14 )
AFFO 306   369   788   822  
Weighted average number of common shares outstanding (millions) 157.4   155.3   156.8   148.6  
AFFO per share ($) 1.94   2.37   5.03   5.53  
  1. Included in other cash items on the condensed interim consolidated statements of cash flows to reconcile net income to net cash flows from operating activities.
  2. Excludes unrealized changes on interest rate derivative contracts, amortization, accretion charges, and non-cash implicit interest on tax equity investment structures.
  3. For the three and nine months ended September 30, 2025, excludes current income tax expense related to the partial divestiture of Quality Wind and Port Dover and Nanticoke Wind in 2024 as the amount is classified as an investing activity.
  4. Sustaining capital expenditures net of partner contributions of $1 million and $10 million for the three and nine months ended September 30, 2026, respectively, compared with $2 million and $8 million for the three and nine months ended September 30, 2025.
  5. For the nine months ended September 30, 2026, reflects recognition of $174 million in Clean Technology ITCs filed with the applicable tax authority, representing approximately 30% of eligible Canadian renewables project costs. For the three and nine months ended September 30, 2026 and September 30, 2025, reflects payments received from the Government of Alberta for the settlement of previously disputed off-coal compensation payments as described in the Company’s 2025 annual consolidated financial statements.
  6. For the nine months ended September 30, 2026, current income tax recoveries of $1 million related to prior period acquisition and integration costs. For the three and nine months ended September 30, 2025, net of current income tax recoveries of $1 million and $2 million.
  7. For the three months ended September 30, 2026, other non-recurring items included $3 million of legal costs related to a contractor dispute concerning construction work at the Genesee Repowering project, offset by a $5 million recovery from the settlement of the FERC reactive supply and voltage control service overpayment provision and current income tax expense of $3 million. For the nine months ended September 30, 2026, other non-recurring items included $5 million of legal costs related to a contractor dispute at the Genesee Repowering project, offset by a $5 million recovery from the settlement of the FERC reactive supply and voltage control service overpayment provision and current income tax recoveries of $3 million associated with non-recurring items recognized in prior periods. For the three months ended September 30, 2025, other non-recurring items reflect costs related to the termination of the Halkirk 2 Wind virtual power purchase agreement (VPPA) of $5 million, net of current income tax recoveries of $8 million related to other non-recurring items recognized in the current and prior periods. For the nine months ended September 30, 2025, other non-recurring items reflect costs related to the termination of the Halkirk 2 Wind VPPA and end-of-life of Genesee coal operations of $5 million each, net of current income tax recoveries of $24 million related to other non-recurring items recognized in the current and prior periods.

Forward-looking information

Forward-looking information or statements (collectively, “forward-looking information”) included in this press release are provided to inform our shareholders, potential investors and other stakeholders about management’s assessment of Capital Power’s future plans and operations. This information may not be appropriate for other purposes. The forward-looking information in this press release is generally identified by words such as will, anticipate, believe, plan, intend, target, and expect or similar words that suggest future outcomes.

Material forward-looking information in this press release includes, among other things, expectations regarding:

  • our 2026 adjusted EBITDA and revised sustaining capital expenditures targets, and
  • recoverability of insurance proceeds for submitted claims.

These statements are based on certain assumptions and analyses made by the Company in light of its experience and perception of historical trends, current conditions, expected future developments, and other factors it believes are appropriate including its review of purchased businesses and assets. The material factors and assumptions used to develop this forward-looking information relate to:

  • electricity and other energy (including natural gas) and carbon prices,
  • the Company’s performance,
  • the Company’s business prospects (including potential re-contracting of facilities) and opportunities including expected growth and capital projects,
  • the energy needs of certain jurisdictions,
  • the status and impact of policy, legislation and regulations,
  • effective tax rates,
  • the development and performance of technology,
  • the outcome of claims and disputes,
  • foreign exchange rates, and
  • other matters discussed under the Performance Outlook and Risks and Risk Management sections of the MD&A.

Whether actual results, performance or achievements will conform to our expectations and predictions is subject to a number of known and unknown risks and uncertainties which could cause actual results and experience to differ materially from our expectations. Such material risks and uncertainties include:

  • Meta’s completion of a data centre as contemplated in the ESA,
  • changes in electricity, natural gas and carbon prices in markets in which we operate and the use of derivatives,
  • regulatory and political environments including changes to environmental, climate, financial reporting, market structure and tax legislation,
  • disruptions, or price volatility within our supply chains,
  • generation facility availability, wind capacity factor and performance including maintenance expenditures,
  • ability to fund current and future capital and working capital needs,
  • acquisitions and developments including timing and costs of regulatory approvals and construction,
  • changes in market prices and the availability of fuel,
  • ability to realize the anticipated benefits of acquisitions,
  • limitations inherent in our review of acquired assets,
  • changes in general economic and competitive conditions, including inflation and recession,
  • changes in the performance and cost of technologies and the development of new technologies, new energy efficient products, services and programs, and
  • risks and uncertainties discussed under the Risks and Risk Management section of the MD&A.

See Risks and Risk Management in our 2025 Integrated Annual Report, for further discussion of these and other risks.

Readers are cautioned not to place undue reliance on any such forward-looking information, which speak only as of the date made and that other events or circumstances, although not listed above, could cause Capital Power’s actual results to differ materially from those estimated or projected and expressed in, or implied by the forward-looking information. Capital Power does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking information to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

About Capital Power

Capital Power is one of North America’s leading independent power producers, with approximately 12 GW of generation capacity across 35 facilities. Our portfolio includes natural gas, renewables, and battery energy storage solutions. We deliver power generation at utility-scale through a flexible and resilient fleet built to meet growing electricity demand. Backed by an investment-grade credit rating, we provide safe, reliable power communities can depend on.

For more information, please contact:

Media Relations: 
Katherine Perron
(780) 392-5335 
kperron@capitalpower.com
Investor Relations: 
Noreen Farrell
(403) 461-5236 
investor@capitalpower.com


1
AFFO and adjusted EBITDA are non-GAAP financial measures. See Non-GAAP Financial Measures and Ratios.

RESTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), a nuclear fuel technology company developing Lightbridge Fuel™ to produce more power from existing and new reactors, today reported financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its fuel development activities.

Third Quarter 2026 and Recent Business Highlights

  • Lightbridge was selected for the DOE Nuclear Energy Launch Pad INL program. In August 2026, Lightbridge was selected to participate in the program, which is administered by DOE’s National Reactor Innovation Center (NRIC) at Idaho National Laboratory (INL). Selection provides an accelerated pathway toward DOE authorization for the Company to design, build, and operate the Lightbridge Fuel™ Pilot Factory (Pilot Factory), which the Company also refers to as SHED, at INL to manufacture lead test assemblies (LTAs) of Lightbridge Fuel™ for demonstration in U.S. commercial power reactors. The Company is negotiating the applicable agreements and project scope with NRIC and INL. Authorization to construct and operate the Pilot Factory remains subject to additional DOE/INL agreements, reviews, and authorizations.
  • Secured loop irradiation testing of clad fuel rodlets in the Advanced Test Reactor (ATR). In August 2026, the Company entered into Project Task Statement (PTS) No. 2 under its Cooperative Research and Development Agreement (CRADA) with Battelle Energy Alliance, LLC (BEA), the DOE operating contractor for INL. The work covers experimental design, materials, assembly, irradiation, shipment, and disposition of enriched uranium-zirconium fuel rodlets with cladding, in both cylindrical and multi-lobe geometries, irradiated in the ATR loop facility under controlled conditions representative of a commercial reactor.
  • Post-irradiation examination of the first fuel samples is currently underway. The first batch of Lightbridge Fuel™ material coupon samples, discharged from the ATR on schedule in May 2026, is currently undergoing post-irradiation examination at INL.
  • Expanded patent protection in Japan. In September 2026, the Japan Patent Office issued a notice of allowance for the Company’s multi-zone fuel element patent application, with allowed claims covering the fuel element design, a fuel assembly containing it, and an additive manufacturing method for producing it. Japan operates 32 reactors, 15 of which have returned to service, and its national energy plan targets nuclear at approximately 20% of electricity generation by fiscal 2040.

Management Commentary

“Selection for the Launch Pad INL program can help to accelerate our commercialization plan,” said Seth Grae, Chairman and Chief Executive Officer of Lightbridge. “Rather than waiting for a commercial fuel factory to be licensed before we could manufacture lead test assemblies, we now have a pathway toward DOE authorization for a dedicated Pilot Factory at INL, and we are negotiating the agreements and project scope with NRIC and INL. In parallel, the loop irradiation agreement we signed in August will enable irradiation testing of the clad Lightbridge Fuel rodlets in the ATR under the conditions similar to those in commercial pressurized water reactors. We believe the loop irradiation will allow us to go from the ATR directly to lead test assemblies in commercial nuclear power plants, rather than first deploying segments of fuel rods and lead test rods in commercial reactors.”

“Our path to acceleration comes at a pivotal moment for the nuclear sector, as major technology companies and utilities increasingly turn to nuclear energy to meet surging baseload power demand from AI, data centers, and industrial electrification. This requires getting substantially more power and higher capacity factors out of the existing nuclear fleet, alongside new builds. Utilities consistently tell us they want three things from an advanced fuel: longer operating cycles between refuelings, power uprates of 10% to 20% from the same plant footprint and operating license, and inherent safety margins that reduce capital and operating costs. Lightbridge Fuel is engineered specifically to meet those requirements.”

Financial Highlights

Working capital was approximately $234.2 million at September 30, 2026, compared to approximately $201.7 million at December 31, 2025.

Cash Flows Summary

Cash and cash equivalents totaled $236.7 million at September 30, 2026, compared to $201.9 million at December 31, 2025, an increase of $34.8 million. Cash equivalents consisted primarily of U.S. Treasury instruments with maturities of 30 to 90 days.

  • Net cash used in operating activities was $13.2 million for the nine months ended September 30, 2026, compared to $8.1 million for the nine months ended September 30, 2025, reflecting higher research and development (R&D) and general and administrative (G&A) spending, partially offset by higher interest income.
  • Net cash provided by financing activities was $48.1 million for the nine months ended September 30, 2026, compared to $121.4 million for the same period in 2025. The Company sold approximately 4.3 million shares of common stock under its at-the-market (ATM) program during the nine months ended September 30, 2026, for net proceeds of $48.9 million, including 579,685 shares for net proceeds of $4.5 million in the third quarter. As of September 30, 2026, approximately $91.4 million of common stock remained available for sale under the Company’s $150 million ATM program.

Third Quarter 2026 Operations Summary

  • G&A expenses were $5.0 million for the three months ended September 30, 2026, compared to $3.2 million for the three months ended September 30, 2025. The $1.8 million increase reflects a $0.9 million increase in employee compensation and stock-based compensation for employees, contractors, and directors, driven by new hires, higher bonuses, and new stock-based awards; a $0.7 million increase in professional and consulting services; and a $0.2 million increase in other administrative expenses, including information technology, insurance, patent, and travel costs.
  • R&D expenses were $5.3 million for the three months ended September 30, 2026, compared to $2.0 million for the three months ended September 30, 2025. The $3.3 million increase reflects a $1.9 million increase in employee compensation and stock-based compensation from new hires, higher bonuses, and new stock-based awards; a $1.0 million increase in information technology expenses, primarily computer software and operating costs for the Company’s high-performance computer; and a $0.4 million increase in INL project costs as the Company entered into additional agreement modifications and new PTSs.
  • Total non-cash stock-based compensation expense was $2.4 million for the three months ended September 30, 2026, compared to $1.6 million for the three months ended September 30, 2025. Stock-based compensation included in G&A was $1.6 million, compared to $1.1 million in the prior-year quarter. Stock-based compensation included in R&D was $0.8 million, compared to $0.5 million in the prior-year quarter.
  • Other income was $2.0 million for the three months ended September 30, 2026, compared to $1.1 million for the three months ended September 30, 2025, consisting of interest income earned on higher cash balances invested primarily in U.S. Treasury bills.
  • Net loss was $8.3 million, or $(0.23) per basic and diluted share, for the three months ended September 30, 2026, compared to a net loss of $4.1 million, or $(0.16) per basic and diluted share, for the three months ended September 30, 2025.

Nine Months Ended September 30, 2026 Operations Summary

G&A expenses were $13.0 million for the nine months ended September 30, 2026, compared to $9.2 million for the nine months ended September 30, 2025. The $3.8 million increase reflects a $2.4 million increase in employee compensation and stock-based compensation, a $1.0 million increase in professional and consulting services, and a $0.4 million increase in other administrative expenses.

  • R&D expenses were $12.6 million for the nine months ended September 30, 2026, compared to $5.3 million for the nine months ended September 30, 2025. The $7.3 million increase reflects a $4.3 million increase in employee compensation and stock-based compensation; a $1.7 million increase in information technology expenses, including software, operating costs for the Company’s high-performance computer, and code development; a $0.6 million increase in INL project costs; a $0.4 million increase in project development costs, primarily critical heat flux testing and safety analysis; and a $0.3 million increase in other outside R&D expenses.
  • Total non-cash stock-based compensation expense was $6.3 million for the nine months ended September 30, 2026, compared to $3.6 million for the nine months ended September 30, 2025. Stock-based compensation included in G&A was $4.4 million, compared to $2.7 million in the prior period. Stock-based compensation included in R&D was $1.9 million, compared to $0.9 million in the prior period. The 2026 total stock-based compensation expense included a $0.7 million reversal recorded in the second quarter of previously recognized stock-based compensation for a performance milestone no longer deemed probable of achievement, of which $0.5 million was included in G&A and $0.2 million was included in R&D.
  • Other income was $5.2 million for the nine months ended September 30, 2026, compared to $2.1 million for the nine months ended September 30, 2025.
  • Net loss was $20.4 million, or $(0.62) per basic and diluted share, for the nine months ended September 30, 2026, compared to a net loss of $12.4 million, or $(0.55) per basic and diluted share, for the nine months ended September 30, 2025.

CONFERENCE CALL & AUDIO WEBCAST

Lightbridge will hold a conference call and audio webcast today, Monday, November 2, 2026, at 4:00 p.m. Eastern Time to discuss its third quarter fiscal 2026 financial results and provide an update on its fuel development activities. Seth Grae, Chairman and Chief Executive Officer, will lead the call, and other members of the executive team will be available to answer questions.

To access the call by phone, please dial 1-800-715-9871 (International dialers can dial 1-646-307-1963) with Conference ID 8688160. To avoid delays, we encourage participants to dial in to the conference call 15 minutes before the scheduled start time and have the Conference ID handy.

An audio webcast can be accessed at the following link (webcast). The Company encourages participants to take advantage of the webcast option.

A webcast replay will also be available for a limited time at the following link (webcast replay).

About Lightbridge Corporation 
Lightbridge Corporation (Nasdaq: LTBR) is focused on developing advanced nuclear fuel technology essential to delivering abundant clean energy and providing energy security to the world. The Company is developing Lightbridge Fuel™, a proprietary next-generation nuclear fuel technology for existing light water reactors and pressurized heavy water reactors, significantly enhancing reactor safety, economics, and proliferation resistance. The Company is also developing Lightbridge Fuel for new small modular reactors to deliver the same benefits, plus load-following.

Lightbridge has entered into two long-term framework agreements with Battelle Energy Alliance, LLC, the United States Department of Energy’s operating contractor for Idaho National Laboratory, the United States’ lead nuclear energy research and development laboratory. DOE’s Gateway for Accelerated Innovation in Nuclear program has twice awarded Lightbridge to support the development of Lightbridge Fuel over the past several years. An extensive worldwide patent portfolio backs Lightbridge’s innovative fuel technology. Lightbridge is included in the Russell 2000®, Russell 3000®, and Solactive Global Uranium and Nuclear Components Total Return Indexes. For more information, please visit www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at https://www.ltbridge.com/investors/news-events/email-alerts  

Lightbridge is on YouTube. Subscribe to access past demonstrations, interviews, and other video content at https://www.youtube.com/@lightbridgecorporation

Lightbridge is on X (formerly Twitter). Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp. 

Forward Looking Statements 

With the exception of historical matters, the matters discussed herein are forward-looking statements. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to: Lightbridge’s ability to commercialize its nuclear fuel technology; the degree of market adoption of Lightbridge’s product and service offerings; Lightbridge’s ability to fund general corporate overhead and outside research and development costs; market competition; our ability to attract and retain qualified employees; dependence on strategic partners; demand for fuel for nuclear reactors; Lightbridge’s ability to manage its business effectively in a rapidly evolving market; the availability of nuclear test reactors and the risks associated with unexpected changes in Lightbridge’s fuel development timeline; the increased costs associated with metallization of Lightbridge’s nuclear fuel; public perception of nuclear energy generally; changes in the political environment; risks associated with war in Europe and the Middle East; changes in the laws, rules and regulations governing Lightbridge’s business; development and utilization of, and challenges to, Lightbridge’s intellectual property; risks associated with potential shareholder activism; potential and contingent liabilities; as well as other factors described in Lightbridge’s filings with the Securities and Exchange Commission (the “SEC”). Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise, except as required by law. Readers are cautioned not to put undue reliance on forward-looking statements.

A further description of risks and uncertainties can be found in Lightbridge’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its other filings with the SEC, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Statements,” all of which are available at http://www.sec.gov/ and www.ltbridge.com.  

Investor Relations Contact: 
Matthew Abenante, IRC 
Senior Director of Investor Relations & Capital Markets  
Tel: +1 (347) 947-2093  
ir@ltbridge.com

*** tables follow ***

LIGHTBRIDGE CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

  September 30,   December 31,
  2026   2025
ASSETS
Current Assets
Cash and cash equivalents $ 236,735,081      $ 201,862,421   
Prepaid expenses and other current assets   1,274,477        712,983   
Total Current Assets   238,009,558        202,575,404   
Other Assets
Prepaid project costs and other long-term assets   2,755,892        1,140,000   
Trademarks   127,187        119,391   
Total Assets $ 240,892,637      $ 203,834,795   
           
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued liabilities $ 3,830,512      $ 847,451   
Total Current Liabilities   3,830,512        847,451   
           
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 authorized shares, no shares issued and outstanding at September 30, 2026 and December 31, 2025   —        —   
Common stock, $0.001 par value, 100,000,000 authorized shares, 38,761,010 shares and 33,407,495 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively   38,761        33,407   
Additional paid-in capital   441,219,021        386,719,120   
Accumulated deficit   (204,195,657 )     (183,765,183 )
Total Stockholders’ Equity   237,062,125        202,987,344   
Total Liabilities and Stockholders’ Equity $ 240,892,637      $ 203,834,795   
               

LIGHTBRIDGE CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

  Three Months Ended   Nine Months Ended
  September 30,   September 30,
  2026     2025     2026     2025  
Revenue $ —      $ —      $ —      $ —   
               
Operating Expenses
General and administrative   5,039,852        3,164,343        13,084,565        9,146,989   
Research and development   5,300,753        2,039,857        12,556,332        5,345,635   
Total Operating Expenses   10,340,605        5,204,200        25,640,897        14,492,624   
                       
Operating Loss   (10,340,605 )     (5,204,200 )     (25,640,897 )     (14,492,624 )
                       
Other Income
Interest income   2,009,488        1,104,955        5,210,423        2,101,933   
Total Other Income   2,009,488        1,104,955        5,210,423        2,101,933   
                       
Net Loss Before Income Taxes   (8,331,117 )     (4,099,245 )     (20,430,474 )     (12,390,691 )
Income taxes   —        —        —        —   
Net Loss $ (8,331,117 )   $ (4,099,245 )   $ (20,430,474 )   $ (12,390,691 )
                       
Net Loss Per Common Share
Basic and diluted $ (0.23 )   $ (0.16 )   $ (0.62 )   $ (0.55 )
                       
Weighted Average Number of Common Shares Outstanding
Basic and diluted   35,470,698        25,624,598        33,152,970        22,498,638   
                               

LIGHTBRIDGE CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

  Nine Months Ended
September 30,
  2026     2025
Operating Activities          
Net Loss $ (20,430,474 )   $ (12,390,691 )
           
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   6,323,764        3,746,642   
           
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (486,494 )     (808,317 )
Prepaid project costs and other long-term assets   (1,615,892 )     201,657   
Accounts payable and accrued liabilities   2,977,061        1,135,512   
Net Cash Used in Operating Activities   (13,232,035 )     (8,115,197 )
           
Investing Activities          
Trademarks   (7,796 )     (6,117 )
Net Cash Used in Investing Activities   (7,796 )     (6,117 )
           
Financing Activities          
Proceeds from sale of common stock in public offerings   50,655,941        124,659,368   
Issuance costs related to sale of common stock in public offerings   (1,774,741 )     (4,207,920 )
Net proceeds from the exercise of stock options   10,807        1,243,794   
Payments for taxes related to net share settlement of equity awards   (779,516 )     (234,621 )
Net Cash Provided by Financing Activities   48,112,491        121,460,621   
           
Net Increase in Cash and Cash Equivalents   34,872,660        113,339,307   
Cash and Cash Equivalents, Beginning of Period   201,862,421        39,990,827   
Cash and Cash Equivalents, End of Period $ 236,735,081      $ 153,330,134   
           

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth

AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth

SUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth

SYMBRAVO® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth

SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated

Company to host conference call today at 8:00 AM Eastern Time

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update.

“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. “Our industry-leading neuroscience pipeline continued to advance, leading to multiple anticipated regulatory and clinical trial milestones in the coming quarters. Our commercial and research and development performance positions us to continue to deliver innovation targeting significant unmet needs in brain health, with the potential to improve the lives of millions of patients.”

Third Quarter 2026 Financial Highlights

  • Total net product revenue was $259.7 million for the third quarter of 2026, representing 52% year-over-year growth. Total net product revenue for the comparable period in 2025 was $171.0 million.
  • AUVELITY net product sales were $207.6 million for the third quarter of 2026, representing 53% year-over-year growth. AUVELITY net product sales for the comparable period in 2025 were $136.1 million.
  • SUNOSI net product revenue was $48.2 million for the third quarter of 2026, representing 47% year-over-year growth, which consisted of $38.5 million in net product sales, $1.2 million in royalty revenue associated with SUNOSI sales in out-licensed territories, and $8.5 million in milestone revenue. SUNOSI net product revenue for the comparable period in 2025 was $32.8 million, which consisted of $31.6 million in net product sales and $1.2 million in royalty revenue.
  • SYMBRAVO net product sales were $3.9 million for the third quarter of 2026, representing 88% year-over-year growth. SYMBRAVO net product sales for the comparable period in 2025 were $2.1 million.
  • Total cost of revenue was $17.8 million for the third quarter of 2026. Total cost of revenue for the comparable period in 2025 was $11.9 million.
  • Research and development (R&D) expenses were $50.6 million for the third quarter of 2026, compared to $40.2 million for the comparable period in 2025. The increase primarily reflects costs for the ongoing clinical programs for solriamfetol, AXS-14, and AXS-05.
  • Selling, general, and administrative (SG&A) expenses were $203.1 million for the third quarter of 2026, compared to $150.2 million for the comparable period in 2025. The increase primarily reflects commercialization activities for AUVELITY and SYMBRAVO.
  • Net loss for the third quarter of 2026 was $12.9 million, or $(0.25) per share, compared to a net loss of $47.2 million, or $(0.94) per share, for the comparable period in 2025. The net loss in the third quarter of 2026 includes $26.4 million in stock-based compensation expense.
  • Cash and cash equivalents totaled $313.9 million at September 30, 2026, compared to $322.9 million at December 31, 2025.
  • Shares of common stock outstanding were 52,576,839 at September 30, 2026.

Financial Guidance

  • Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

Commercial Highlights

AUVELITY

AUVELITY is a first‑in‑class oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma‑1 receptor agonist approved in the U.S. for the treatment of major depressive disorder in adults, and for the treatment of agitation associated with dementia due to Alzheimer’s disease.

  • Approximately 302,000 total prescriptions were written for AUVELITY in the third quarter of 2026, representing year-over-year and quarter-over-quarter increases of 40% and 14%, respectively. New-to-brand prescriptions, representing new AUVELITY patient starts, increased by 44% year-over-year and 21% quarter-over-quarter.
  • Third quarter AUVELITY new-to-brand and total prescriptions among patients aged 65 years and older increased by 211% and 101%, respectively, compared to the third quarter of 2025. Third quarter AUVELITY new-to-brand and total prescriptions among patients aged 65 years and older increased by 99% and 43%, respectively, compared to the second quarter of 2026.
  • Payer coverage for AUVELITY across all channels is currently at approximately 89% of all lives covered. The proportion of lives covered in the commercial and government (Medicare and Medicaid) channels are approximately 82% and 100%, respectively.

SUNOSI

SUNOSI is the first and only dopamine and norepinephrine reuptake inhibitor (DNRI) approved for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy.

  • Approximately 64,400 prescriptions were written for SUNOSI in the U.S. in the third quarter of 2026, a 15% increase compared to the same period in 2025, and a 6% increase compared to the second quarter of 2026.
  • Payer coverage for SUNOSI across all channels is at approximately 82% of all lives covered, including approximately 97% of commercial lives and 59% of government lives.

SYMBRAVO

SYMBRAVO is an oral, rapidly absorbed, multi-mechanistic, COX-2 preferential inhibitor and 5-HT1B/1D agonist approved in the U.S. for the acute treatment of migraine with or without aura in adults.

  • Approximately 25,000 prescriptions were written for SYMBRAVO in the third quarter of 2026, a 382% increase compared to the same period in 2025, and a 7% increase compared to the second quarter of 2026.
  • Payer coverage for SYMBRAVO across all channels is at approximately 57% of all lives covered, including approximately 56% of commercial lives and 57% of government lives.

Development Pipeline

Axsome is advancing an industry-leading neuroscience pipeline of multiple, innovative product candidates addressing a broad range of serious psychiatric and neurological conditions. Recent and anticipated progress for key pipeline programs is summarized below.

AXS-05

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor being developed for smoking cessation.

  • Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation. The Company anticipates topline results from the SUMMIT Phase 3 trial in the second half of 2027.

Solriamfetol

Solriamfetol is Axsome’s DNRI, TAAR1 agonist, and 5-HT1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with EDS symptoms, binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

  • Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.
  • Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.
  • Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.
  • Major Depressive Disorder: Axsome is conducting the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD with EDS symptoms. The Company anticipates completion of enrollment in CLARITY in the first half of 2027.

AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, investigational, highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator being developed for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for narcolepsy.

  • Narcolepsy: Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.

AXS-14

AXS-14 (esreboxetine) is Axsome’s novel, oral, investigational, highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of reboxetine.

  • Fibromyalgia: Axsome is conducting the FORWARD study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of AXS-14 for the management of fibromyalgia. The Company anticipates completion of enrollment in the FORWARD Phase 3 trial in the third quarter of 2027.

AXS-17

AXS-17 is Axsome’s novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator (PAM) being developed for the treatment of epilepsy.

  • Epilepsy: Axsome plans to initiate clinical trials of AXS-17 in epilepsy in the first half of 2027.

AXS-20

AXS-20 (balipodect) is Axsome’s novel oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor being developed for the treatment of schizophrenia.

  • Schizophrenia: Axsome plans to initiate a pivotal Phase 3 trial of AXS-20 in schizophrenia in the first half of 2027.

Anticipated Milestones

  • Clinical Trial Initiations:
    • Phase 1B trial of AXS-17 in epilepsy (1H 2027)
    • Phase 3 trial of AXS-20 in schizophrenia (1H 2027)
  • Clinical Trial Topline Results:
    • Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (1Q 2027)
    • Phase 3 SUSTAIN trial of solriamfetol in shift work disorder (2H 2027)
    • Phase 3 FOCUS-2 trial of solriamfetol in children with ADHD (2H 2027)
    • Phase 3 FOCUS-3 trial of solriamfetol in adolescents with ADHD (2H 2027)
    • Phase 3 SUMMIT trial of AXS-05 in smoking cessation (2H 2027)
  • Regulatory and Commercial:
    • AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)

Conference Call Information

Axsome will host a conference call and webcast today at 8:00 a.m. Eastern Time to discuss its third quarter 2026 financial results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. A replay of the conference call will be available for approximately 30 days following the live event.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements.” The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Axsome Therapeutics, Inc.
Selected Consolidated Financial Data

Axsome Therapeutics, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
             
    September 30,
2026
    December 31,
2025
 
    (Unaudited)        
Assets            
Current assets:            
Cash and cash equivalents   $ 313,859     $ 322,933  
Accounts receivable, net     343,114       224,464  
Inventories, net     42,579       27,938  
Prepaid and other current assets     25,084       13,651  
Total current assets     724,636       588,986  
Equipment, net     943       562  
Right-of-use asset – operating lease     18,284       20,858  
Goodwill     12,042       12,042  
Intangible asset, net     35,751       40,519  
Non-current inventory and other assets     35,117       26,838  
Total assets   $ 826,773     $ 689,805  
Liabilities and stockholders’ equity            
Current liabilities:            
Accounts payable   $ 96,075     $ 65,537  
Accrued expenses and other current liabilities     331,756       232,853  
Operating lease liability, current portion     663       434  
Contingent consideration, current     11,225       10,012  
Short-term borrowings     70,000       70,000  
Total current liabilities     509,719       378,836  
Contingent consideration, non-current     63,610       77,540  
Loan payable, long-term     118,069       117,746  
Operating lease liability, long-term     20,748       23,182  
Finance lease liability, long-term     9,193       4,206  
Total liabilities     721,339       601,510  
Stockholders’ equity:            
Preferred stock, $0.0001 par value per share (10,000,000 shares
authorized, none issued and outstanding)
    —       —  
Common stock, $0.0001 par value per share (150,000,000 shares
authorized, 52,576,839 and 50,882,766 shares issued and outstanding at
September 30, 2026 and December 31, 2025, respectively)
    5       5  
Additional paid-in capital     1,540,123       1,394,251  
Accumulated deficit     (1,434,694 )     (1,305,961 )
Total stockholders’ equity     105,434       88,295  
Total liabilities and stockholders’ equity   $ 826,773     $ 689,805  
Axsome Therapeutics, Inc.
Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share amounts)
             
    Three months ended
September 30,
    Nine months ended
September 30,
 
    2026     2025     2026     2025  
Revenues:                        
Product sales, net   $ 249,951     $ 169,784     $ 655,706     $ 439,101  
Royalty revenue and milestone revenue     9,740       1,208       13,563       3,396  
Total revenues     259,691       170,992       669,269       442,497  
Operating expenses:                        
Cost of revenue (excluding amortization and depreciation)     17,804       11,912       46,093       35,149  
Research and development     50,617       40,162       149,521       134,488  
Selling, general and administrative     203,111       150,235       596,244       401,302  
Loss (Gain) in fair value of contingent consideration     (2,380 )     13,185       (3,286 )     6,595  
Intangible asset amortization     1,607       1,607       4,768       4,768  
Total operating expenses     270,759       217,101       793,340       582,302  
Loss from operations     (11,068 )     (46,109 )     (124,071 )     (139,805 )
Interest expense, net     (1,721 )     (1,120 )     (4,446 )     (5,385 )
Loss on debt extinguishment     —       —       —       (10,385 )
Loss before income taxes     (12,789 )     (47,229 )     (128,517 )     (155,575 )
Income tax benefit (expense)     (88 )     —       (216 )     960  
Net loss   $ (12,877 )   $ (47,229 )   $ (128,733 )   $ (154,615 )
Net loss per common share, basic and diluted   $ (0.25 )   $ (0.94 )   $ (2.48 )   $ (3.13 )
Weighted average common shares outstanding, basic and diluted     52,445,193       50,021,851       51,818,984       49,449,220  


Investors:

Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:

Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that the Company will host a conference call on Tuesday, November 10, 2026, at 8:00 a.m. ET to discuss its business strategy and financial results for the third quarter ended September 30, 2026. The Company’s results will be reported in a press release prior to the call.

Vireo Growth management will host the conference call, followed by a question-and-answer period. Interested parties can join the conference call by dialing in as directed below. Please dial-in 10 minutes prior to the call.

Date: Tuesday, November 10, 2026
Time: 8:00 a.m. Eastern Time
Toll-free dial-in number: +1 833 461 5787
International dial-in numbers 
Meeting ID: 406388419

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/406388419

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Contact Information:

Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com 
(781) 956-7052

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the U.S. financial markets on Monday, November 9, 2026.

Kamada’s management will host an investment community conference call on Monday, November 9, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13763380. The call will be webcast live on the internet at:
https://viavid.webcasts.com/starthere.jsp?ei=1779441&tp_key=96a5dea210.

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates targeting areas of significant unmet medical need.

CONTACTS:

Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.